Skip to main content
. 2021 Nov 2;31(8):1293–1307. doi: 10.1093/hmg/ddab317

Figure 2.

Figure 2

Ighmbp2 D564N/D564N mice have reduced survival and weight that is improved in a dose-dependent manner with ssAAV9-IGHMBP2. (A) Survival of Ighmbp2+/+ mice (green), Ighmbp2+/D564N mice (orange), Ighmbp2D564N/D564N mice (red) and Ighmbp2D564N/D564N mice treated with either a low dose (1 × 1011 viral genomes-purple) or a high dose (5 × 1011 viral genomes-blue) of ssAAV9-IGHMBP2. Statistical analysis performed using the log-rank (Mantel-Cox) test. Median survival of Ighmbp2D564N/D564N mice was 17 days (n = 24). (B) Weight differences between the five cohorts listed above. The average peak weight of Ighmbp2D564N/D564N mice was 3.83 ± 0.1399 g (n = 24). (C) Representative image at PND16 of wild-type, Ighmbp2D564N/D564N and Ighmbp2D564N/D564N mice treated with a low dose (1 × 1011 viral genomes) of ICV injected ssAAV9-IGHMBP2. (D) Representative image at PND16 of wild-type, Ighmbp2D564N/D564N and Ighmbp2D564N/D564N mice treated with a high dose (5 × 1011 viral genomes) of ICV injected ssAAV9-IGHMBP2. Data bars expressed as mean ± SEM ****P < 0.0001, * indicates significance.